Gene Profiling of Basal Cell Carcinomas Treated with Imiquimod
Author Information
Author(s): Panelli Monica C, Stashower Mitchell E, Slade Herbert B, Smith Kina, Norwood Christopher, Abati Andrea, Fetsch Patricia, Filie Armando, Walters Shelley-Ann, Astry Calvin, Aricó Eleonora, Zhao Yingdong, Selleri Silvia, Wang Ena, Marincola Francesco M
Primary Institution: National Institutes of Health
Hypothesis
Characterizing early transcriptional events induced by imiquimod may provide insights about immunological events preceding acute tissue and/or tumor rejection.
Conclusion
The study provides insights into the early transcriptional events associated with immune rejection in basal cell carcinoma treated with imiquimod.
Supporting Evidence
- Imiquimod is effective in inducing immune responses against basal cell carcinoma.
- Nine out of 22 imiquimod-treated BCCs were found to be clear of tumor cells.
- Significant increases in immune cell markers were observed post-treatment.
Takeaway
This study looked at how a cream called imiquimod helps the body fight skin cancer by making the immune system work better.
Methodology
The study involved a paired analysis of punch biopsies from patients treated with imiquimod or a control cream, assessing gene expression changes.
Potential Biases
Potential biases may arise from patient compliance and variability in treatment adherence.
Limitations
The study did not assess the long-term effects of treatment and relied on a relatively small sample size.
Participant Demographics
61% had nodular BCC, 17% superficial BCC, and 22% unspecified BCC.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website